The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations
Open accessAbstract
Purpose: BRAF mutations occur in non–small-cell lung cancer. Therapies targeting BRAF mutant tumors have recently been identified. We undertook this study to determine the clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. Patients and Methods: We reviewed data from consecutive patients with lung adenocarcinoma whose tumors underwent BRAF, EGFR, and KRAS mutation testing as well as fluorescence in situ hybridization for ALK rearrangements. Patient characteristics including age, sex, race, performance status, smoking history, stage, treatment history, and overall survival were collected. Results: Among 697 patients with lung adenocarcinoma, BRAF mutations were present in 18 patients (3%; 95% CI, 2% to 4%). The BRAF mutations identified were V600E (50%), G469A (39%), and D594G (11%). Mutations in EGFR were present in 24%, KRAS in 25%, and ALK translocations in 6%. In contrast to patients with EGFR mutations and ALK rearrangements who were mostly never smokers, all patients with BRAF mutations were current or former smokers (P < .001). The median overall survival of advanced-stage patients with BRAF mutations was not reached. In comparison, the median overall survival of patients with EGFR mutations was 37 months (P = .73), with KRAS mutations was 18 months (P = .12), and with ALK rearrangements was not reached (P = .64). Conclusion: BRAF mutations occur in 3% of patients with lung adenocarcinoma and occur more commonly in current and former smokers. The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The most common is a valine to glutamate substitution at codon 600 (V600E), which accounts for more than 90% of the BRAF mutations in melanoma.(8) Substitution of this negatively charged amino acid for valine is thought to eliminate a protein–protein interaction between the activation segment and glycine P-loop that n…”
BackgroundEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,870
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & Varmus, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,516
Self-citationBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Riely, G. J., Pao, W., Pham, D., Li, A. R., Rizvi, N., Venkatraman, E. S., Zakowski, M. F., Kris, M. G., Ladanyi, M., & Miller, V. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1846 · Cited by 731
Self-citationSorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., Gibbens, I., Hackett, S., James, M., Schuchter, L. M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603291 · Cited by 644
Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
Riely, G. J., Kris, M. G., Rosenbaum, D., Marks, J., Li, A., Chitale, D. A., Nafa, K., Riedel, E. R., Hsu, M., Pao, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0646 · Cited by 578
Self-citationForbes, S. A., Tang, G., Bindal, N., Bamford, S., Dawson, E., Cole, C., Kok, C. Y., Jia, M., Ewing, R., Menzies, A., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp995 · Cited by 573
Dankort, D., Filenova, E., Collado, M., Serrano, M., Jones, K., & McMahon, M. (2007) · Genes & Development · doi:10.1101/gad.1516407 · Cited by 481
Yang, H., Higgins, B., Kolinsky, K., Packman, K., Go, Z., Iyer, R., Kolis, S., Zhao, S., Lee, R., Grippo, J. F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0646 · Cited by 407
Kefford, R., Arkenau, H., Brown, M. P., Millward, M., Infante, J. R., Long, G. V., Ouellet, D., Curtis, M., Lebowitz, P. F., & Falchook, G. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8503 · Cited by 275
Pan, Q., Pao, W., & Ladanyi, M. (2005) · The Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60569-7 · Cited by 248
Self-citationFlaherty, K., Puzanov, I., Sosman, J., Kim, K., Ribas, A., McArthur, G., Lee, R. J., Grippo, J. F., Nolop, K., & Chapman, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9000 · Cited by 229
MALDI-TOF Mass Spectrometry : A Versatile Tool for High-Performance DNA Analysis
Jurinke, C., Oeth, P., & van den Boom, D. (2004) · Molecular Biotechnology · doi:10.1385/mb:26:2:147 · Cited by 224
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
Smalley, K. S. M., Xiao, M., Villanueva, J., Nguyen, T. K., Flaherty, K. T., Letrero, R., Van Belle, P., Elder, D. E., Wang, Y., Nathanson, K. L., et al. (2009) · Oncogene · doi:10.1038/onc.2008.362 · Cited by 216
Pham, D., Kris, M. G., Riely, G. J., Sarkaria, I. S., McDonough, T., Chuai, S., Venkatraman, E. S., Miller, V. A., Ladanyi, M., Pao, W., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3224 · Cited by 212
Self-citationBRAF as therapeutic target in melanoma
Wellbrock, C., & Hurlstone, A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.019 · Cited by 178
Ji, H., Wang, Z., Perera, S. A., Li, D., Liang, M.-C., Zaghlul, S., McNamara, K., Chen, L., Albert, M., Sun, Y., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4592 · Cited by 174
Detection of KRAS and BRAF Mutations in Colorectal Carcinoma
Arcila, M. E., Lau, C., Nafa, K., & Ladanyi, M. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.005 · Cited by 148
Self-citationBRAF, a target in melanoma: Implications for solid tumor drug development
Flaherty, K. T., & McArthur, G. A. (2010) · Cancer · doi:10.1002/cncr.25261 · Cited by 139
Schwartz, G. K., Robertson, S., Shen, A., Wang, E., Pace, L., Dials, H. J., Mendelson, D. S., Shannon, P., & Gordon, M. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3513 · Cited by 95
Uncommon V599E BRAF Mutations in Japanese Patients with Lung Cancer
Sasaki, H., Kawano, O., Endo, K., Suzuki, E., Haneda, H., Yukiue, H., Kobayashi, Y., Yano, M., & Fujii, Y. (2005) · Journal of Surgical Research · doi:10.1016/j.jss.2005.10.022 · Cited by 68
Kris, M. G., Lau, C. Y., Ang, D. C., Brzostowski, E. B., Riely, G. J., Rusch, V. W., Jhanwar, S. C., Lash, A., Zakowski, M. F., & Ladanyi, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.7009 · Cited by 16
Self-citation
Cited by
Lung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,283
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Non-small cell lung cancer: current treatment and future advances
Zappa, C., & Mousa, S. A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.07 · Cited by 1,944
Metadata
- Authors
- Paik, P. K., Arcila, M. E., Fara, M., Sima, C. S., Miller, V. A., Kris, M. G., Ladanyi, M., & Riely, G. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-05-20
- Volume
- 29
- Issue
- 15
- Pages
- 2046-2051
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160304102
- Cited by
- 691
- References
- 31
- FWCI
- 50.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.